US STOCKS · SEC COMPANY PROFILE
Gilead Sciences
GILEAD SCIENCES, INC. · Nasdaq
Gilead develops and sells medicines for HIV, liver disease, cancer and other serious illnesses.
Visit Gilead Sciences’s official websiteReported revenue spread evenly through elapsed UTC time. Refresh does not restart it; it resets at midnight UTC.
For every $100 of reported revenue
2026-01-01–2026-06-30 · ratios from the same reported period
Profit includes accounting items that may not involve cash today. Operating cash flow measures cash from operations; capital spending covers the reported investment measure. These ratios help compare scale, but industry, seasonality and one-time items still matter. They are not a breakdown that adds to $100.
Revenue by product group
Acquired in-process research and development charges can create a large reported loss while operating cash flow remains positive; those charges are different from recurring product margins. Segment shares are calculated from consolidated revenue for the same period.
GILD stock price
TradingView supplies updated market data automatically. The chart starts with one-hour intervals; the current interval can change as trades arrive. Exchange delays and availability are shown by the provider.
WORLD NUMBERS ASSESSMENTCompany Health Score
Expand for the score breakdown and outlookMixed overall healthCash, growth, profits and investment · review the assumptions below6/10View details
Company Health Score
Expand for the score breakdown and outlookMixed overall health
Our assessment of the reported financial position and the company-specific outlook.
Higher means stronger overall financial health under this model. This is World Numbers’ subjective assessment, not an official rating or a prediction of the stock price. It does not establish that shares are good value.
10.2% change in latest-quarter revenue from the comparable year-earlier quarter.
-57.4% net margin for the reported 181-day period. One-time gains or charges can affect this measure.
$5.86B operating cash flow after cash capital spending for the same reported period. This is a calculation, not all investing or financing activity.
HIV medicines and new launches can support revenue; clinical trials, patents and acquisition-related research charges can change reported profit.
Looking ahead
HIV medicines and new launches can support revenue; clinical trials, patents and acquisition-related research charges can change reported profit. This is a speculative editorial interpretation of the filing’s business and risk discussion, not quantified issuer guidance.
How we arrived at the score
Cash scores use cash ÷ liabilities: at least 0.5 scores 9, 0.25 scores 8, 0.1 scores 6; otherwise 4. Revenue growth scores: at least 30% scores 9, 10% scores 8, non-negative scores 6; otherwise 3. Net margin scores: at least 20% scores 9, 10% scores 8, non-negative scores 6; otherwise 3. Cash after investment ÷ revenue scores: at least 15% scores 9, 5% scores 8, non-negative scores 6; otherwise 3. Future outlook is an editorial score. The weighted result is 6.33, rounded to 6. These thresholds and weights are judgment choices, not statistically validated probabilities. The assessment uses data through 2026-06-30; it does not update each second.
Net loss
Latest quarter: -$10.5B net loss · -134.5% net margin
Q1 2027 at this pace: -$4,214,088,398Reported total ÷ 181 days × elapsed UTC time. Refresh does not restart this estimate; it resets at midnight UTC.Operating cash flow
Reported cash flow from operations
Q1 2027 at this pace: $3,041,602,210Reported total ÷ 181 days × elapsed UTC time. Refresh does not restart this estimate; it resets at midnight UTC.Capital spending
Cash property, plant and equipment purchases; acquisition and financing payments are separate.
Q1 2027 at this pace: $127,790,055Reported total ÷ 181 days × elapsed UTC time. Refresh does not restart this estimate; it resets at midnight UTC.Current leadership
Daniel P. O’Day
Chief executive officer
Leadership is checked separately from annual compensation. The historical pay table below may cover different roles or former executives.
Leadership check and financial reporting dates are separate. Annual total compensation is updated when a new compensation disclosure is published; quarterly earnings do not necessarily include it.
Reported executive pay
Three executives from the dated compensation disclosure. Names, roles and pay below describe that disclosure and do not establish who leads the company today.
Why use this pay period? The latest reviewed proxy reports fiscal 2025 compensation. The publication date is different from the period being paid. Annual counters spread historical reported pay across the current calendar year; they are not current payroll.
Daniel P. O’Day
Historical disclosure: Chairman & CEO
- Salary reported · 2025
- $1,795,192
- Total pay reported · 2025
- $28,437,198
- Shares held or eligible to buy
- 1,968,853
- Current value of reported shares
- Not calculated The chart’s quote is provided separately. We do not multiply historical ownership by an unverified price or treat conditional awards as cash.
Total includes grant-date accounting values of stock or options, incentives, benefits and pension changes where reported. It is not all cash received.
Andrew D. Dickinson
Historical disclosure: CFO
- Salary reported · 2025
- $1,116,654
- Total pay reported · 2025
- $8,765,616
- Shares held or eligible to buy
- 376,017
- Current value of reported shares
- Not calculated The chart’s quote is provided separately. We do not multiply historical ownership by an unverified price or treat conditional awards as cash.
Total includes grant-date accounting values of stock or options, incentives, benefits and pension changes where reported. It is not all cash received.
Johanna Mercier
Historical disclosure: Chief commercial & corporate affairs officer
- Salary reported · 2025
- $1,182,269
- Total pay reported · 2025
- $9,300,643
- Shares held or eligible to buy
- 633,994
- Current value of reported shares
- Not calculated The chart’s quote is provided separately. We do not multiply historical ownership by an unverified price or treat conditional awards as cash.
Total includes grant-date accounting values of stock or options, incentives, benefits and pension changes where reported. It is not all cash received.
Total compensation can include grant-date accounting values of stock or options and benefits. It is not necessarily cash received. Ownership date: 2026-02-28. Dated proxy ownership snapshot. Counts include common shares and qualifying rights acquirable within 60 days when included in beneficial ownership; deferred, phantom and non-voting stock units are excluded. A market-price illustration is not the cash value of options after exercise costs.
Employees
Workforce and pay-ratio populations can differ. Median total pay is the middle disclosed employee, not average salary. This page divides the first displayed executive’s compensation-table total by median pay, which can differ from the issuer’s official ratio. Employee counts are reported snapshots and do not tick. Companies use different employee populations and pay-ratio methods, so comparisons need care.
Revenue & net income
Revenue appears in blue above net income in pink. Net margin is net income divided by revenue. These are reported results, not estimates.
2025-06-30
2026-06-30
What changed?
$7.8B versus $7.08B in the comparable quarter a year earlier. The dollar change was $721M.
-$10.5B net income versus $1.96B a year earlier. Net income includes expenses and other gains or charges; it is not a measure of cash in the bank.
Acquired in-process research and development charges can create a large reported loss while operating cash flow remains positive; those charges are different from recurring product margins. For the 181-day cash-flow period, operating cash flow less cash capital spending was $5.86B.
Watch next quarter
HIV medicines and new launches can support revenue; clinical trials, patents and acquisition-related research charges can change reported profit. Next earnings date: consult the company’s confirmed announcements; no unverified calendar date is displayed.
What was reported at 2026-06-30
Balances update when a new filing is verified. Investment categories differ; only the labeled short-term category is displayed.
Valuation, returns & earnings
Capital returns & voting rights
Dividend and repurchase payments are historical cash outflows, not future commitments or dividend yield.
Dated proxy ownership snapshot. Counts include common shares and qualifying rights acquirable within 60 days when included in beneficial ownership; deferred, phantom and non-voting stock units are excluded. A market-price illustration is not the cash value of options after exercise costs. Reported executive ownership is dated 2026-02-28; balances and market values are different measures.
Gilead Sciences financial questions, explained
How much revenue does Gilead Sciences generate per day and per second?
The reviewed SEC 10-Q reports $14,763,000,000 from 2026-01-01 through 2026-06-30, covering 181 days. Dividing by those actual days gives $81,563,536 per day and $944 per second. The counter illustrates that historical rate across each UTC day; it is not live sales or management guidance. Acquired in-process research and development charges can create a large reported loss while operating cash flow remains positive; those charges are different from recurring product margins.
Read the SEC sourceWhat were Gilead Sciences’s latest quarterly revenue and earnings?
For the quarter ended 2026-06-30, revenue was $7,803,000,000 and net income was $-10,496,000,000, a -134.5% net margin. Revenue in the comparable year-earlier quarter was $7,082,000,000. Reported net income includes accounting gains, expenses and charges; it is not cash collected.
Read the SEC sourceWhere does Gilead Sciences’s reported revenue come from?
Revenue by product group: HIV: $10,723,000,000 (72.6%); Liver disease: $1,644,000,000 (11.1%); Oncology: $1,683,000,000 (11.4%); Veklury: $167,000,000 (1.1%); Other products: $357,000,000 (2.4%); Royalty & contract: $189,000,000 (1.3%). These amounts cover 2026-01-01 through 2026-06-30. Product and geographic breakdowns are labeled as such and should not be mistaken for separate operating segments.
Read the SEC sourceHow much compensation did Daniel P. O’Day report at Gilead Sciences?
The latest reviewed proxy reports $1,795,192 salary and $28,437,198 total compensation for fiscal 2025. Chairman & CEO. Total includes grant-date accounting values of stock or options, incentives, benefits and pension changes where reported. It is not all cash received. The annual-pay counter is an illustration spread through the current calendar year, not evidence of cash being paid every second.
Read the SEC sourceHow many employees does Gilead Sciences report, and what is median pay?
The annual filing reports 17,000 employees as of 2025-12-31. The proxy reports median total employee compensation of $238,979 for Fiscal 2025. Median means the middle employee in the disclosed population, not an average base salary. Workforce and pay-ratio populations can differ. Median total pay is the middle disclosed employee, not average salary. This page divides the first displayed executive’s compensation-table total by median pay, which can differ from the issuer’s official ratio.
Read the SEC sourceDoes Gilead Sciences’s operating cash flow cover reported capital spending?
Reported operating cash flow was $6,117,000,000 and cash capital spending was $257,000,000 for the 181-day period. Subtracting spending gives $5,860,000,000. Cash property, plant and equipment purchases; acquisition and financing payments are separate. This calculation does not include all investing or financing activity.
Read the SEC sourceDoes Gilead Sciences pay a cash dividend?
The reviewed period shows $2,069,000,000 of cash dividend payments. That is a historical total, not dividend yield or a promise about future payments. Dividend and repurchase payments are historical cash outflows, not future commitments or dividend yield.
Read the SEC sourceWhat should investors watch in Gilead Sciences’s next report?
Watch HIV sales and new prevention medicines, Cancer and liver disease pipeline, Acquisition charges and recurring cash flow. HIV medicines and new launches can support revenue; clinical trials, patents and acquisition-related research charges can change reported profit. The next-quarter counters hold the reported daily rate unchanged. They are World Numbers scenarios, not issuer guidance or stock-price predictions.
Read the SEC sourceReporting period: 2026-01-01–2026-06-30 · filed 2026-08-06 · last completed verification 2026-10-08 · page updated 2026-10-26
How World Numbers calculates estimatesHow the estimates work
We divide each reported flow by its actual 181-day reporting period. The daily rate is spread evenly over elapsed UTC time and resets at midnight. Refreshing the page does not restart the counter. The next-calendar-quarter illustration holds that pace unchanged; it is not live sales or a company forecast. Annual executive pay is spread across the current calendar year, including leap-year day counts. Stock awards, balances, employees and shares are not current payroll or live counts. Company-specific limitations: Acquired in-process research and development charges can create a large reported loss while operating cash flow remains positive; those charges are different from recurring product margins.